This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Capranico, G. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by Capranico, G. Articles by Zunino, F.

Change of the Sequence Specificity of Daunorubicin-stimulated Topoisomerase II DNA Cleavage by Epimerization of the Amino Group of the Sugar Moiety¹

Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy

Antitumor drugs stimulate topoisomerase II-mediated DNA cleavage in a DNA sequence-specific manner. The drug sequence specificity is often very similar among antitumor agents of the same chemical class. In this work, we demonstrate, however, that 3'-epidaunorubicin has a markedly different sequence specificity as compared with the parent drugs daunorubicin and doxorubicin. The analogue stimulates distinct cleavage intensity patterns in agarose and sequencing gels with two different DNA substrates, although its cleaving activity was lower than that of daunorubicin. A statistical analysis of 44 sites specifically stimulated by the analogue showed that a major difference between the analogue and parent drugs was at position -2, where a guanine is highly preferred by the analogue, whereas parent drugs prefer a thymine and exclude instead a guanine. Interestingly, an analogue with no substituents at the 3'-C of the sugar was able to stimulate DNA cleavage at sites stimulated by parent drugs as well as at those stimulately by 3'-epidaunorubicin. In contrast, the presence of a 2'-OH or a 3'-epi-OH in the sugar moiety and the removal of the OH at 9-C of the A ring did not alter the drug site selectivity, in agreement with several other modifications studied previously. DNA binding affinities of studied agents were not related to drug sequence specificity. The data demonstrate a critical role of the 3' position for optimal anthracycline interactions in the ternary complex. The findings, for the first time, establish a clear relationship between a specific drug substituent and base sequence selectivity and indicate putative DNA- and enzyme-interacting domains of the anthracycline molecule.

¹ This work has been partially supported by the Associazione Italiana per la Ricerca sul Cancro, Milan, Italy, and by Consiglio Nazionale delle Ricerche, "Progetto Finalizzato ACRO," Rome, Italy.

² To whom requests for reprints should be addressed, at Division of Experimental Oncology B, Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy.

Received 8/24/94. Accepted 11/ 9/94.

This article has been cited by other articles:

				M. J. Arauzo-Bravo and A. Sarai Indirect readout in drug-DNA recognition: role of sequence-dependent DNA conformation Nucleic Acids Res., February 2, 2008; 36(2): 376 - 386. [Abstract] [Full Text] [PDF]

				M. Binaschi, R. Farinosi, M. E. Borgnetto, and G. Capranico In Vivo Site Specificity and Human Isoenzyme Selectivity of Two Topoisomerase II-poisoning Anthracyclines Cancer Res., July 1, 2000; 60(14): 3770 - 3776. [Abstract] [Full Text]

				F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, F. Animati, S. Manzini, F. Zunino, G. Kohlhagen, Y. Pommier, et al. Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines Mol. Pharmacol., July 1, 1999; 56(1): 77 - 84. [Abstract] [Full Text]

				C. Bailly, X. Qu, F. Anizon, M. Prudhomme, J.-F. Riou, and J. B. Chaires Enhanced Binding to DNA and Topoisomerase I Inhibition by an Analog of the Antitumor Antibiotic Rebeccamycin Containing an Amino Sugar Residue Mol. Pharmacol., February 1, 1999; 55(2): 377 - 385. [Abstract] [Full Text]

				M. Binaschi, G. Capranico, L. Dal Bo, and F. Zunino Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity Mol. Pharmacol., June 1, 1997; 51(6): 1053 - 1059. [Abstract] [Full Text]